

this represents the *terminal* vinyl carbon comes from the undecoupled spectrum in which this peak appears as a triplet. Thus **4** is not involved in the formation of the vinyl compound.

The detailed mechanism of rearrangement remains to be worked out as do the structures of any possible intermediates analogous to those postulated in the phenylcarbene rearrangement. Although even gross questions remain (can the carbene rearrangement traverse borons on its way to stability?), it is clear that one of our initial questions has been answered—the *o*-carborane polyhedral frame can act as a transport system for a carbene. To this extent the analogy between benzene and its three-dimensional cousin holds.

Acknowledgment. We thank Professor Paul v. R. Schleyer for stimulating our interest in carboranes and for convincing us that carboranes are tractable compounds.

References and Notes

- (1) Support from the National Science Foundation through Grant CHE 77-24625 is gratefully acknowledged.
- (2) (a) Jones, W. M.; Brinker, U. H. In "Pericyclic Reactions", Marchand, A. P., Lehr, R. E., Eds.; Academic Press: New York, 1977; Vol. 1, Chapter 3. (b) Vander Stouw, G. G.; Kraska, A. R.; Shechter, H. J. *Am. Chem. Soc.* **1972**, *94*, 1655. (c) Wentrup, C. *Top. Curr. Chem.* **1976**, *62*, 173. (d) Jones, M., Jr. *Acc. Chem. Res.* **1974**, *7*, 415. (e) For a different "nonclassical" phenylcarbene rearrangement, see Brinker, U. H.; Jones, W. M. *Tetrahedron Lett.* **1976**, 577.
- (3) (a) Grimes, R. N. "Carboranes"; Academic Press: New York, 1970. (b) Onak, T. "Organoborane Chemistry"; Academic Press: New York, 1975. (c) Beall, H. In "Boron Hydride Chemistry"; Muettterties, E. L., Ed.; Academic Press: New York, 1975; Chapter 9.
- (4) (a) Preliminary results of S. Chari indicate that, at least for 1-carboranylcarbene in solution, they are. (b) Chari, S., preliminary results.
- (5) Chambers, G. R.; Jones, M., Jr. *Tetrahedron Lett.* **1978**, 5193. Sekiguchi, A.; Ando, W. *Bull. Chem. Soc. Jpn.* **1977**, *50*, 3067.
- (6) Dexsil Chemical Corp., Hamden, Conn.
- (7) Generation of phenylcarbene in the gas phase gives small amounts of toluene for instance: Pacala, L. A.; Font, J.; Hollowood, F., unpublished results.
- (8) Zakharkin, L. I.; Grebinnekov, A. V.; Kazantsev, A. V. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1967**, 2077.
- (9) For reports of three-membered rings containing metals, see: Zakharkin, L. I.; Kovredov, A. I. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1975**, 2619. Sayler, A. A.; Beall, H.; Sieckhaus, J. F. *J. Am. Chem. Soc.* **1973**, *95*, 5790.
- (10) (a) Adcock, W.; Gupta, B. D.; Khor, T. C.; Dodderell, D.; Kitching, W. J. *Org. Chem.* **1976**, *41*, 751. (b) Todd, L. J.; Seidle, A. R.; Bodner, G. M.; Kahl, S. B.; Hickey, J. P. *J. Magn. Reson.* **1976**, *23*, 301.
- (11) Baron, W. J.; DeCamp, M. R. *Tetrahedron Lett.* **1973**, 4225.
- (12) Dhami, K. S.; Stothers, J. B. *Can. J. Chem.* **1965**, *43*, 510.

Sarangan Chari, Garabed K. Agopian
Maitland Jones, Jr.*

Department of Chemistry, Princeton University
Princeton, New Jersey 08544


Received April 9, 1979

A Total Synthesis of Pentostatin,¹ the Potent Inhibitor of Adenosine Deaminase

Sir:

Pentostatin¹⁻³ (**9a**) has been shown to be the most potent inhibitor known⁴ for adenosine deaminase (adenosine aminohydrolase, E.C. 3.5.4.4), the enzyme responsible for the N⁶-deamination of adenine nucleosides. This compound has generated considerable interest as a potentially useful drug for use in combination with certain adenine nucleosides, especially ara-A,⁵ whose antiviral and antitumor properties⁶⁻⁹ are greatly enhanced, both in vitro and in vivo, in the presence of minuscule amounts of pentostatin. Moreover, pentostatin has alone demonstrated a most unique activity as an immunosuppressant,^{10,11} acting to prevent the maturation of lymphocytes to limit their role in the immune response.

Herein is described a total, practical synthesis of pentostatin from an available imidazole precursor. In attacking the problem of a total synthesis, it was early recognized that the



problem was essentially twofold: (1) developing a synthesis of the unique, chiral, five- and seven-membered fused-ring heterocyclic aglycone, and (2) devising a scheme whereby the fragile 2-deoxy sugar could be efficiently incorporated in the synthetic sequence.¹²

Toward developing a synthesis of the heterocyclic moiety, a diamine **6** was envisioned as a reasonable precursor for the 1,3-diazepinone **7**, the latter being formed via insertion of a one-carbon fragment into **6**. To this end, the chemistry evolved in the following manner. 5-Nitro-4-styrylimidazole (**1**), prepared by an improvement in the published procedure¹³ from the condensation of 4-methyl-5-nitroimidazole and benzaldehyde in base (>80%), afforded, upon benzylation with benzyl chloride in *N,N*-dimethylformamide-potassium carbonate, an ~75:25 mixture (>95%) of the benzyl isomers **2a** and **2b**, respectively.¹⁴ Ozonolysis of the mixture of **2a** and **2b**, followed by oxidation of the ozonide with performic acid, gave the crystalline carboxylic acid **3**, isolated directly from the reaction mixture: 75%; mp 155–156 °C dec; $\lambda_{\text{max}}^{\text{MeOH}}$ 290 nm (ϵ 4350); $\nu(\text{C}=\text{O})$ 1736 cm^{-1} ; NMR δ 5.50 (s, 2, $-\text{CH}_2\text{Ph}$), 7.37 (m, 5, aryl), 8.17 (s, 1, 2H).¹⁵ Elaboration of the $-\text{CH}_2\text{N}<$ portion of the molecule, usually a most difficult process, was achieved in a straightforward manner by C-acylation of potassium methanidenitronate, using the imidazolyl derivative of the acid **3**, a new process¹⁶ found to be exceedingly useful for a general synthesis of α -nitro ketones. Data for **4**: 75% yield; mp 107–108.5 °C; $\lambda_{\text{max}}^{\text{MeOH}}$ 298 nm (ϵ 4900); $\nu(\text{C}=\text{O})$ 1642 (NO_2), 1561 cm^{-1} ; NMR δ 5.61 (s, 2, $-\text{CH}_2\text{Ph}$), 6.27^{17a} (s, 2, $-\text{CH}_2\text{NO}_2$), 7.22–7.46 (m, 5, aryl), 8.42 (s, 1, 2H). Reduction of the nitro groups on **4** was cleanly effected using 6 equiv of tin(II) chloride in concentrated hydrochloric acid to give the *N*-benzyl diamine dihydrochloride **5** (74%; mp 155 °C dec; $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ 303 nm (ϵ 13 200); $\nu(\text{C}=\text{O})$ 1620 cm^{-1} ; NMR δ 4.14 (d, 2, $J = 6.0$ Hz, $-\text{CH}_2\text{NH}_2$), 5.33 (s, 2, $-\text{CH}_2\text{Ph}$), 7.36

(s, 5, aryl), 8.25 (s, 1, 2H)) as a white, crystalline solid. Debenzylation was achieved by hydrogenolysis over a palladium-on-charcoal catalyst at pH <2 to furnish the free diamine dihydrochloride **6** (96%; mp >250 °C dec, chars by 310 °C; $\lambda_{\text{max}}^{112\text{O}}$ 304 nm (ϵ 11 700); NMR δ 4.13 (d, 2, J = 6.0 Hz, $-\text{CH}_2\text{NH}_3^+$), 8.28 (s, 1, 2H)) as a highly organic-insoluble, brittle solid. Using an ethanol-methyl sulfoxide solution of triethyl orthoformate, ring closure to **7**^{17b} was effected cleanly and efficiently (88%; mp >250 °C dec; $\lambda_{\text{max}}^{\text{MeOH}}$ 300, 227 nm (ϵ 3360, 17 200); $\nu(\text{C}=\text{O})$ 1682 cm^{-1} ; NMR δ 4.33 (s, 2, $-\text{CH}_2\text{NH}-$), 8.08, 8.24 (s, s, 1, 1, 2-H and 5-H)),¹⁷ in contrast to low-yielding syntheses reported for other 1,3-diazepins.¹⁸ Glycosylation of the per(trimethylsilyl)ated **7** with 2-deoxy-3,5-di-*O*-(*p*-toluoyl)-*D*-erythro-pentofuranosyl chloride in 1,2-dichloroethane gave an anomeric mixture of the protected nucleosides **8a** and **8b**, isolated from byproducts of the reaction by a rapid chromatography over a bed of silica gel, using ethyl acetate-methanol as the eluant. The anomeric nucleosides were separated by crystallization from ethyl acetate to give the less soluble α anomer **8b** (15%; mp 220 °C dec; $[\alpha]_{\text{D}}^{23} +1.8$, $[\alpha]_{\text{D}}^{436} +28^\circ$ (c 1, DMF); $\lambda_{\text{max}}^{\text{MeOH}}$ 350, 300, 282 and 235 nm (ϵ 3744, 2789, 3040, 51 258); NMR δ 2.23–3.11 (m, 2, H-2', 2'a), 2.37, 2.47 (s, s, 3, 3, PhCH_3), 3.73 (m, 2, $-\text{NHCH}_2\text{C}=\text{O}$), 4.47 (m, 2, H-5', 5'a), 4.93 (m, 1, H-4'), 5.60 (dd 1, H-3'), 6.42 (dd, 1, H-1', $J_{1',2'} = 2.3$, $J_{1',2'a} = 6.8$ Hz), 7.4, 7.9 (m, 10, aryl), 8.44, 8.48 (s, s, 1, 1, H-2, H-5)) followed by the β anomer **8a** (14%; mp 129–155 °C dec; $[\alpha]_{\text{D}}^{23} -35$, $[\alpha]_{\text{D}}^{436} -87^\circ$ (c 1, DMF); NMR δ 2.06–3.02 (m, 2, H-2', 2'a), 2.36, 2.47 (s, s, 3, 3, PhCH_3), 3.76 (m, 2, $-\text{NHCH}_2\text{C}=\text{O}$), 4.42 (m, 1, H-4'), 4.52 (m, 2, H-5', 5'a), 5.64 (dd, H-3'), 6.42 (t, 1, H-1', $J_{1',2'} \approx J_{1',2'a} = 6.8$ Hz)).¹⁹ The anomeric nucleosides **8a** and **8b** are clearly distinguished on the basis of the characteristic doublet of doublets exhibited by the H-1' signal of the α anomer **8b**, while its β counterpart **8a** gave a pseudotriplet. The H-4' signal for the α anomer **8b** was also shifted downfield owing to the apparent deshielding effects of the heterocyclic ring. A wide divergence in optical activity, coupled with identical UV spectra under acidic, neutral, and basic conditions, further substantiated the assignments of these compounds as an anomeric pair (as opposed to possible positional isomers).

Deacylation of **8a** in sodium methoxide-methanol, followed by reduction of the crude, keto nucleoside with sodium borohydride, afforded an ~60:40 mixture of *R* and *S* alcohols **9a** and **9b**, having 60 $\pm$ 5% of the activity of natural pentostatin. Separation of the diastereomeric pair using a preparative, reverse-phase, octadecylsilyl-derivatized column of silica gel gave the pure *R* isomer that was identical with authentic pentostatin by TLC (silica gel), reverse-phase LC, optical rotation, and UV and NMR spectroscopy; **9a** showed 100 $\pm$ 5% of the adenosine deaminase inhibitory activity of natural pentostatin.

Acknowledgment. The foregoing work was supported by National Cancer Institute Contract NO1-CM-23708 to Warner-Lambert/Parke-Davis.

References and Notes:

- (a) Pentostatin is the USAN-approved generic name for (*R*)-3-(2-deoxy- β -*D*-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-*d*][1,3]-diazepin-8-ol, formerly referred to (see ref 2 and 3) as covidarabine (CoV) and occasionally as 2'-deoxycoviformycin (2'-dCF). (b) For a preliminary account, see Baker, D. C.; Putt, S. R. Abstracts of Papers, the American Chemical Society Meeting of the Southern Arizona Section, C.S. Marvel Symposium, Tucson, Ariz., March 19–20, 1979; U.S. Patent 4 117 229.
- Woo, P. W. K.; Dion, H. W.; Lange, S. M.; Dahl, L. F.; Durham, L. J. *Heterocycl. Chem.* **1974**, *11*, 641–643.
- Dion, H. W.; Woo, P. W. K.; Ryder, A. *Ann. N.Y. Acad. Sci.* **1977**, *284*, 21–29.
- Agarwal, R. P.; Spector, T.; Parks, Jr., R. E. *Biochem. Pharmacol.* **1977**, *26*, 359–367.
- Ara-A is 9- β -*D*-arabinofuranosyladenine (VIRA-A), trademark of Parke-Davis & Co.
- Schwartz, P. M.; Shipman, Jr., C.; Drach, J. C. *Antimicrob. Agents Chemother.* **1976**, *10*, 64–74.
- Schabel, Jr., F. M.; Trader, M. W.; Laster, Jr., W. R. *Proc. Am. Assoc. Cancer Res.* **1976**, *17*, Abstr. 181.
- Le Page, G. A.; Worth, L. S.; Kimbal, A. P. *Cancer Res.* **1976**, *36*, 1481–1485.
- Cass, C. E.; A-Yeung, T. H. *Cancer Res.* **1976**, *36*, 1486–1491.
- Lum, C. T.; Sutherland, D. E. R.; Najarian, J. R. *New Engl. J. Med.* **1977**, *296*, 819.
- Chassin, M. M.; Chirigos, M. A.; Johns, D. G.; Adamson, R. H. *New Engl. J. Med.* **1977**, *296*, 1232.
- An approach utilized in the synthesis of coformycin (Ohno, M.; Yagisawa, N.; Shibahara, S.; Kondo, S.; Maeda, K.; Umezawa, H. *J. Am. Chem. Soc.* **1974**, *96*, 4326–4327) was deemed ineffective for a synthesis of pentostatin.
- Windaus, A.; Langenbeck, W. *Ber.* **1923**, *56*, 683–686.
- The isomers were easily separated by column chromatography over silica gel (dichloromethane eluant). The structure of each isomer was established by conversion of both 1-benzyl-4-methyl-5-nitroimidazole and 1-benzyl-5-methyl-4-nitroimidazole (structures unambiguous by NMR) into their respective styryl counterparts **2a** and **2b** via condensation of each separately with benzaldehyde.
- NMR data are reported for ~1–2% solutions in $\text{Me}_2\text{SO}-d_6$ (tetramethylsilane internal standard) run on a Bruker WH-90 instrument. All compounds described as "isolated" in the text gave acceptable elemental analyses.
- Baker, D. C.; Putt, S. R. *Synthesis* **1978**, 478–479.
- (a) Disappears upon addition of deuterium oxide. (b) Compound **7** was frequently encountered as $7 \cdot \text{HCl} \cdot \text{Me}_2\text{SO}$, mp 156–157 °C dec.
- deStevens, G. *Top. Heterocycl. Chem.* **1969**, Chapter 6.
- Yields, especially in the case of the glycosylation process, have been greatly improved during the process development phase of this work: Baker, D. C.; Chan, E.; Putt, S. R.; Showalter, H. D. H., unpublished work.
- Address correspondence to the Department of Chemistry, The University of Alabama, University, Ala. 35486.

David C. Baker,*²⁰ S. R. Putt

Department of Chemistry

Warner-Lambert/Parke-Davis Research Division

Ann Arbor, Michigan 48107

Received May 31, 1979

Asymmetric Addition of Hydrogen Cyanide to Alkenes Catalyzed by a Zerovalent Palladium Compound

Sir:

We report herein that addition of hydrogen cyanide to alkenes can be carried out in high yields and with significant amounts (~30%) of asymmetric induction when transition metal catalysts with chiral ligands are used. Many asymmetric hydrogenation reactions have been reported,¹ but in contrast few examples have been published in which new carbon-carbon bonds have been formed. Two examples where significant asymmetric induction has been achieved are in reactions of norbornene with other alkenes² and in catalytic allylic alkylations.³

Reaction of hydrogen cyanide with norbornene using a palladium catalyst which we formulate as [(+)-DIOP]Pd⁴ gave 2-*exo*-cyanonorbornane, $[\alpha]_{\text{D}} +3.4^\circ$ in which the (1*S*,2*S*,4*R*)-(+)-enantiomer predominated (Scheme I). This was demonstrated by hydrolysis to the corresponding carboxylic acid which had $[\alpha]_{\text{D}} +3.0^\circ$. The pure (1*S*,2*S*,4*R*) enantiomer has $[\alpha]_{\text{D}} +10.7^\circ$ ⁵ and thus the optical induction is 28%. When reactions were carried out with a deficiency of hydrogen cyanide (32 mmol) vs. norbornene (64 mmol) in benzene at 130 °C in the presence of [(+)-DIOP]Pd (0.09 mmol) the yield of 2-*exo*-cyanonorbornane was 40%. This yield increased to 80% when a small amount of free (+)-DIOP (0.025 mmol) was added. Reaction with this amount of (+)-DIOP, but at lower temperature (80 °C), gave a lower yield (40%) but a slight increase in optical induction (31%). Reaction with equimolar amounts (64 mmol) of norbornene and hydrogen cyanide at 130 °C in the presence of (+)-DIOP and catalyst gave 2-cyanonorbornane (53%) with similar optical induction (29%). Addition of a Lewis acid, e.g., ZnCl_2 , for a reaction in acetonitrile solution did not lead to any improvement in yield⁶ or optical yield.

Reaction of norbornadiene under similar conditions gave